Sen-Jam Pharmaceutical

Aug 12, 2025

Sen-Jam Pharmaceutical Positions SJP-002C as a Transformative Complement to GLP-1 Therapies and a Standalone Solution for MASH

Mar 11, 2025

Sen-Jam Pharmaceutical Welcomes Immunology and Infectious Disease Expert Dr. Ashley St. John to its Scientific Advisory Board

Jan 27, 2025

Sen-Jam Pharmaceutical Answers Surgeon General's Alarm with a New Therapeutic Aimed at Tackling Alcohol Related Risks

Jan 15, 2025

Sen-Jam Pharmaceutical Announces Preliminary Results from Phase 2 Clinical Trials of SJP-002C for Upper Respiratory Infections/COVID-19

Jan 14, 2025

Sen-Jam Pharmaceutical Announces Ethics Approval in Australia for SJP-001 Clinical Trial Targeting Inflammation and Metabolic Health

Jan 10, 2025

Sen-Jam Pharmaceutical Announces Planned AI Initiative for Molecule Repurposing

Nov 19, 2024

Sen-Jam Pharmaceutical Advances First in Class FDA-Regulated Hangover Prevention Therapy Tackling Inflammation to Phase 2 Clinical Trials

Jun 24, 2024

Sen-Jam Pharmaceutical Completes Enrollment for Phase 2 Upper Respiratory Infection/COVID Therapeutic

May 22, 2024

Sen-Jam Pharmaceutical Announces Upcoming Completion of SJP-002C Clinical Trial, Offering Hope for a Safe, Potent, and Globally Affordable Treatment for Upper Respiratory Infections and COVID-19

Apr 10, 2024

Sen-Jam Pharmaceutical Partners with Specialty Pharmaceutical Manufacturer to Provide Formulation and Chemistry, Manufacturing & Controls for Revolutionary Anti-Inflammatory Injectable